BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thomas MC, Atkins RC. Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 2006;66:2213-34. [PMID: 17137404 DOI: 10.2165/00003495-200666170-00005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Thomas MC, Atkins R. Assessment and management of hypertension in patients with type 2 diabetes. Intern Med J 2009;39:143-9. [PMID: 18771428 DOI: 10.1111/j.1445-5994.2008.01696.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
2 Alexander MP, Patel TV, Farag YM, Florez A, Rennke HG, Singh AK. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009;53:751-759. [PMID: 19339092 DOI: 10.1053/j.ajkd.2009.01.255] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
3 Amazonas RB, de Almeida Sanita R, Kawachi H, Lopes de Faria JB. Prevention of Hypertension with or without Renin-Angiotensin System Inhibition Precludes Nephrin Loss in the Early Stage of Experimental Diabetes Mellitus. Nephron Physiol 2007;107:p57-64. [DOI: 10.1159/000108642] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
4 Glorioso N, Argiolas G, Filigheddu F, Troffa C, Cocco F, Bulla E, Bulla P, Zaninello R, Degortes S, Pitzoi S, Frau F, Fadda S, Pinna Parpaglia P, Bernini G, Bardini M, Fallo F, Malatino L, Regolisti G, Ferri C, Cusi D, Sciacqua A, Perticone F, Degli Esposti E, Baraccani C, Parati G, Veglio F, Mulatero P, Williams TA, Macciardi F, Stancanelli B; Study Group on Cardiovascular Pharmacogenomics of Italian Society of Hypertension. Conceptual basis and methodology of the SOPHIA study. Pharmacogenomics 2007;8:1497-509. [PMID: 18034615 DOI: 10.2217/14622416.8.11.1497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lopes de Faria JB, Silva KC, Lopes de Faria JM. The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress. Hypertens Res 2011;34:413-22. [PMID: 21228783 DOI: 10.1038/hr.2010.263] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
6 Freeman JS, Gross B. Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review. Expert Rev Clin Pharmacol 2012;5:31-42. [PMID: 22142157 DOI: 10.1586/ecp.11.64] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
7 Reboldi G, Gentile G, Manfreda VM, Angeli F, Verdecchia P. Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep 2012;14:89-96. [PMID: 22139528 DOI: 10.1007/s11886-011-0236-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
8 Eckert S, Freytag SB, Müller A, Klebs SH. Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors. Blood Press 2013;22 Suppl 1:11-21. [PMID: 23713686 DOI: 10.3109/08037051.2013.793891] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
9 Locke M, Anderson J. NF-κB activation in organs from STZ-treated rats. Appl Physiol Nutr Metab 2011;36:121-7. [PMID: 21326386 DOI: 10.1139/H10-094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
10 Figarola JL, Loera S, Weng Y, Shanmugam N, Natarajan R, Rahbar S. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia 2008;51:882-91. [DOI: 10.1007/s00125-008-0935-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
11 Yao Y, Fomison-Nurse IC, Harrison JC, Walker RJ, Davis G, Sammut IA. Chronic bilateral renal denervation attenuates renal injury in a transgenic rat model of diabetic nephropathy. Am J Physiol Renal Physiol 2014;307:F251-62. [PMID: 24899056 DOI: 10.1152/ajprenal.00578.2013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
12 Mäkinen VP, Soininen P, Forsblom C, Parkkonen M, Ingman P, Kaski K, Groop PH, Ala-Korpela M; FinnDiane Study Group. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol 2008;4:167. [PMID: 18277383 DOI: 10.1038/msb4100205] [Cited by in Crossref: 124] [Cited by in F6Publishing: 118] [Article Influence: 9.5] [Reference Citation Analysis]
13 Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, Nihei T, Honda K, Suzuki Y, Kawabe Y. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 2013;170:519-31. [PMID: 23751087 DOI: 10.1111/bph.12269] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 9.4] [Reference Citation Analysis]
14 Groop PH, Thomas MC, Moran JL, Wadèn J, Thorn LM, Mäkinen VP, Rosengård-Bärlund M, Saraheimo M, Hietala K, Heikkilä O, Forsblom C; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-8. [PMID: 19401416 DOI: 10.2337/db08-1543] [Cited by in Crossref: 378] [Cited by in F6Publishing: 307] [Article Influence: 31.5] [Reference Citation Analysis]
15 Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag 2009;5:411-27. [PMID: 19475778 DOI: 10.2147/vhrm.s4235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Mäkinen VP, Forsblom C, Thorn LM, Wadén J, Kaski K, Ala-Korpela M, Groop PH. Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (the FinnDiane Study). Cardiovasc Diabetol 2009;8:54. [PMID: 19804653 DOI: 10.1186/1475-2840-8-54] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
17 Naqvi SA, Ahsan S, Fawwad A, Basit A, Shera AS. Effect of angiotensin converting enzyme inhibitor on glomerular hyperfiltration in patients with type 1 diabetes. Pak J Med Sci 2016;32:559-64. [PMID: 27375689 DOI: 10.12669/pjms.323.9399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 van der Kloet FM, Tempels FW, Ismail N, van der Heijden R, Kasper PT, Rojas-Cherto M, van Doorn R, Spijksma G, Koek M, van der Greef J, Mäkinen VP, Forsblom C, Holthöfer H, Groop PH, Reijmers TH, Hankemeier T. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 2012;8:109-19. [PMID: 22279428 DOI: 10.1007/s11306-011-0291-6] [Cited by in Crossref: 101] [Cited by in F6Publishing: 101] [Article Influence: 10.1] [Reference Citation Analysis]
19 Norton JM, Newman EP, Romancito G, Mahooty S, Kuracina T, Narva AS. CE: Improving Outcomes for Patients with Chronic Kidney Disease: Part 1. Am J Nurs 2017;117:22-32. [PMID: 28085685 DOI: 10.1097/01.NAJ.0000512272.33956.8b] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]